

Resource Summary Report

Generated by [RRID](#) on Aug 28, 2026

WERI-Rb-1

RRID:CVCL_1792

Type: Cell Line

Proper Citation

RRID:CVCL_1792

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1792

Proper Citation: RRID:CVCL_1792

Description: Cell line WERI-Rb-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Retinoblastoma

Defining Citation: [PMID:679190](#), [PMID:844036](#), [PMID:1682862](#), [PMID:2751270](#), [PMID:6351622](#), [PMID:7499444](#), [PMID:7689221](#), [PMID:19686387](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:23498719](#), [PMID:25326674](#), [PMID:27115612](#), [PMID:28713896](#), [PMID:29192327](#), [PMID:30584916](#), [PMID:31781967](#), [PMID:32123578](#), [PMID:35409416](#)

Comments: Population: Caucasian., Part of: ENCODE project common cell types; tier 3., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: WERI-Rb-1

Synonyms: WERI-RB-1, WERI-Rb 1, WERI-Rb1, WERI-RB1, WERI Rb-1, WERIRb1, WERI, Wills Eye Research Institute-Retinoblastoma-1

Cross References: CLO:CLO_0009583, CLO:CLO_0009584, CLO:CLO_0051563, EFO:EFO_0005715, CLDB:cl4695, AddexBio:C0029002/4899, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ATCC:HTB-169, BioSample:SAMN03472730, cancercellines:CVCL_1792, CCRID:3101HUMTCHu213, Cell_Model_Passport:SIDM01414, CLS:300632, Cosmic:688119, Cosmic:909782,

DepMap:ACH-001421, DSMZ:ACC-90, DSMZCellDive:ACC-90, ECACC:06070602, ENCODE:ENCBS087YAE, ENCODE:ENCBS270AAA, ENCODE:ENCBS282DQM, ENCODE:ENCBS283KOW, ENCODE:ENCBS283WND, ENCODE:ENCBS679NMZ, GEO:GSM749679, GEO:GSM749766, GEO:GSM749768, GEO:GSM824870, GEO:GSM945263, GEO:GSM945318, GEO:GSM1486290, GEO:GSM2043881, IGRhCellID:WERIRb1, IZSLER:BS TCL 231, JCRB:JCRB3028, JCRB:KURB2683, Lonza:1147, PRIDE:PXD030924, Progenetix:CVCL_1792, RCB:RCB2146, TKG:TKG 0601, Wikidata:Q54993776

ID: CVCL_1792

Record Creation Time: 20220427T221715+0000

Record Last Update: 20260816T000141+0000

Ratings and Alerts

No rating or validation information has been found for WERI-Rb-1.

Warning: Discontinued: JCRB; KURB2683

Population: Caucasian., Part of: ENCODE project common cell types; tier 3., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Sujjitjoon J, et al. (2026) B7-H3 and GD2 overexpression as immunotherapeutic targets in retinoblastoma. Scientific reports, 16(1), 4210.

Gudenas BL, et al. (2026) A tumor-associated photoreceptor signature unifies distinct central nervous system malignancies. Cancer cell, 44(4), 831.

Zhang Z, et al. (2025) The role of lactate metabolism in retinoblastoma tumorigenesis and ferroptosis resistance. Tissue & cell, 95, 102893.

Wang Y, et al. (2024) Targeting ALDOA to modulate tumorigenesis and energy metabolism in retinoblastoma. iScience, 27(9), 110725.

Ryl T, et al. (2024) A MYCN-driven de-differentiation profile identifies a subgroup of aggressive retinoblastoma. Communications biology, 7(1), 919.

Yin J, et al. (2024) Gentiopicroside inhibits retinoblastoma cell proliferation, invasion, and tumorigenesis in nude mice by suppressing the PI3K/AKT pathway. *Naunyn-Schmiedeberg's archives of pharmacology*, 397(2), 1003.

Haase A, et al. (2024) New retinoblastoma (RB) drug delivery approaches: anti-tumor effect of atrial natriuretic peptide (ANP)-conjugated hyaluronic-acid-coated gold nanoparticles for intraocular treatment of chemoresistant RB. *Molecular oncology*.

Pearson JD, et al. (2024) Netrin-1 and UNC5B Cooperate with Integrins to Mediate YAP-Driven Cytostasis. *Cancer research communications*, 4(9), 2374.

Aubry A, et al. (2023) Deneddylation of ribosomal proteins promotes synergy between MLN4924 and chemotherapy to elicit complete therapeutic responses. *Cell reports*, 42(8), 112925.

Pearson JD, et al. (2021) Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. *Cancer cell*, 39(8), 1115.

Hoshino A, et al. (2020) Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. *Cell*, 182(4), 1044.